Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04434131 · ClinicalTrials.gov registry record · Phase 2
Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19
A Phase 2 study, sponsored by University of New Mexico.
- Completed
- Registry status
- Phase 2
- Development phase
- 12
- Enrollment target
NCT04434131 is a Phase 2 study that has completed, run by University of New Mexico. The registered enrollment target is 12 participants.
The verdict
NCT04434131, a Phase 2 study, has completed, sponsored by University of New Mexico.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 12 participants
- Enrollment target
Study Summary
This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in NAb levels in the recipient in hospitalized patients with COVID-19.
Interventions
- DRUG Convalescent Plasma
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2020-04-28 |
| Est. Completion | 2021-03-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04434131
The ClinicalTrials.gov registry entry for NCT04434131 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of New Mexico, which has 168 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Convalescent Plasma is the first listed.
NCT04434131 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04434131 about?
NCT04434131 is a clinical study titled "Treatment With Investigational Convalescent Plasma and Measure Antibody Levels in Patients Hospitalized With COVID-19". This is an open label pilot study designed to provide access to treatment with investigational convalescent plasma and assess the relationship between NAb titers in the investigational convalescent plasma compared to changes in NAb levels in the recipient in hospitalized patients with COVID-19.
What is the current status of trial NCT04434131?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 12 participants. The study started on 2020-04-28. Estimated completion is 2021-03-12.
What interventions are being tested in trial NCT04434131?
The interventions under investigation include: Convalescent Plasma (DRUG).
Who is sponsoring clinical trial NCT04434131?
This trial is sponsored by University of New Mexico, which has 168 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.